937. Baclofen

Nomenclature

CAS number: 1134-47-0
β-(Aminomethyl)-4-chlorobenzenepropanoic acid; β-(aminomethyl)-p-chlorohydrocinnamic acid; γ-amino-β-(p-chlorophenyl)butyric acid; β-(4-chlorophenyl)GABA; Ba-34647; Baclon (Schering AG); Clofen (Julphar); Lioresal (Novartis).
C10H12ClNO2; mol wt 213.66.
C 56.21%, H 5.66%, Cl 16.59%, N 6.56%, O 14.98%.

Description and references

Specific GABA-B receptor agonist. Prepn: NL 6407755; H. Keberle et al., US 3471548 (1965, 1969 both to Ciba). Toxicity study: T. Tadokoro et al., Osaka Daigaku Igaku Zasshi 28, 265 (1976), C.A. 88, 183016u (1978). Comprehensive description: S. Ahuja, Anal. Profiles Drug Subs. 14, 527-548 (1985). Review of pharmacology and therapeutic efficacy in spasticity: R. N. Brogden et al., Drugs 8, 1-14 (1974); of intrathecal use in spinal cord injury: K. S. Lewis, W. M. Mueller, Ann. Pharmacother. 27, 767-774 (1993). Clinical evaluation in reflex sympathetic dystrophy: B. J. van Hilten et al., N. Engl. J. Med. 343, 625 (2000). Benefit-risk assessment in severe spinal spasticity: A. Dario, G. Tomei, Drug Saf. 27, 799-818 (2004).

Chemical structure

Properties

Crystals from water, mp 206-208°. Slightly sol in water; very slightly sol in methanol. Insol in chloroform. LD50 in male mice, rats (mg/kg): 45, 78 i.v.; 103, 115 s.c.; 200, 145 orally (Tadokoro).

Derivative

Hydrochloride.

Nomenclature

CAS number: 28311-31-1
C10H13Cl2NO2; mol wt 250.12.
C 48.02%, H 5.24%, Cl 28.35%, N 5.60%, O 12.79%.

Properties

mp 179-181°.

Therapeutic Category

Muscle relaxant (skeletal).

Therapeutic Category (Veterinary)

Muscle relaxant (skeletal).

Keywords

Muscle Relaxant (Skeletal)